Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells

Oncogene

Volumn 30, Issue 9, 2011, Pages 1009-1019

  Majeti, R ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute myeloid leukemia; cancer stem cells; monoclonal antibodies

Indexed keywords

CD123 ANTIGEN; CD32 ANTIGEN; CD47 ANTIGEN; CD96 ANTIGEN; CLL 1 ANTIGEN; GEMTUZUMAB OZOGAMICIN; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD123; MONOCLONAL ANTIBODY CD44; MONOCLONAL ANTIBODY CD47; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; CANCER STEM CELL; CHIMERA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOXICITY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, CD47; ANTIGENS, SURFACE; DISEASE MODELS, ANIMAL; HUMANS; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASTIC STEM CELLS;

EID: 79952282655     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.511     Document Type: Review

References (66)

1. Adams GP, Weiner LM. (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157. (Pubitemid 41486396)
2. Ailles LE, Gerhard B, Hogge DE. (1997). Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood 90: 2555-2564. (Pubitemid 27413464)
3. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. (1999). Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94: 1761-1772. (Pubitemid 29411327)
4. Bakker AB, van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, Bia JA et al. (2004). C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64: 8443-8450. (Pubitemid 39491785)
5. Barclay AN, Brown MH. (2006). The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464.
6. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. (1992). Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 89: 2804-2808.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. (1976). Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33: 451-458.
8. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. (1997). Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89: 3104-3112. (Pubitemid 27229792)
9. Blair A, Hogge DE, Sutherland HJ. (1998). Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. Blood 92: 4325-4335. (Pubitemid 28544350)
10. Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Old-enborg PA, Iizuka K et al. (2001). CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counter-receptors is required to prevent the clearance of donor lymphohe-matopoietic cells. J Exp Med 194: 541-549. (Pubitemid 32835048)
11. Bonnet D, Dick JE. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hemato-poietic cell. Nat Med 3: 730-737. (Pubitemid 27298715)
12. Brown EJ, Frazier WA. (2001). Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11: 130-135. (Pubitemid 32289443)
13. Burnett AK, Mohite U. (2006). Treatment of older patients with acute myeloid leukemia-new agents. Semin Hematol 43: 96-106.
14. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S et al. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.
15. Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C et al. (1999). Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med 5: 669-676. (Pubitemid 29289431)
16. Cheson BD, Leonard JP. (2008). Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359: 613-626.
17. Craig W, Kay R, Cutler RL, Lansdorp PM. (1993). Expression of Thy-1 on human hematopoietic progenitor cells. J Exp Med 177: 1331-1342. (Pubitemid 23117124)
18. Dalerba P, Cho RW, Clarke MF. (2007). Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284. (Pubitemid 46706514)
19. Dick JE. (2008). Stem cell concepts renew cancer research. Blood 112: 4793-4807.
20. Estey E, Dohner H. (2006). Acute myeloid leukaemia. Lancet 368: 1894-1907. (Pubitemid 44794525)
21. Finn OJ. (2008). Cancer immunology. N Engl J Med 358: 2704-2715.
22. Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR et al. (2006). Detection of molecular targets on the surface of CD34+/CD38-stem cells in various myeloid malignancies. Leuk Lymphoma 47: 207-222. (Pubitemid 43084559)
23. Gilliland DG, Griffin JD. (2002). The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532-1542. (Pubitemid 34925124)
24. Gilliland DG, Jordan CT, Felix CA. (2004). The molecular basis of leukemia. Hematology Am Soc Hematol Educ Program, 80-97.
25. Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grunert C et al. (1998). Antibodies TC-12 ('unique') and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 26: 1209-1214. (Pubitemid 28541763)
26. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M et al. (2007). CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 104: 11008-11013. (Pubitemid 47175217)
27. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G et al. (2005). Development of functional human blood and immune systems in NOD/SCID/IL2 rec. Blood 106: 1565-1573.
28. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321. (Pubitemid 350076512)
29. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R et al. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138: 271-285.
30. Jawad M, Seedhouse C, Mony U, Grundy M, Russell NH, Pallis M. (2010). Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia 24: 74-80.
31. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174. (Pubitemid 44527352)
32. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L et al. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5: 31-42.
33. Jordan CT, Guzman ML, Noble M. (2006). Cancer stem cells. N Engl J Med 355: 1253-1261. (Pubitemid 44427449)
34. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL et al. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.
35. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science 317: 337. (Pubitemid 47106366)
36. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648. (Pubitemid 24067706)
37. Levis M, Murphy KM, Pham R, Kim KT, Stine A, Li L et al. (2005). Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 106: 673-680. (Pubitemid 40981265)
38. Lowenberg B, Downing JR, Burnett A. (1999). Acute myeloid leukemia. N Engl J Med 341: 1051-1062. (Pubitemid 29451802)
39. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs Jr KD et al. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
40. Majeti R, Park CY, Weissman IL. (2007). Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 1: 635-645. (Pubitemid 350215330)
41. Miyamoto T, Weissman IL, Akashi K. (2000). AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 97: 7521-7526. (Pubitemid 30431496)
42. Murray L, Chen B, Galy A, Chen S, Tushinski R, Uchida N et al. (1995). Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood 85: 368-378.
43. Okazawa H, Motegi S, Ohyama N, Ohnishi H, Tomizawa T, Kaneko Y et al. (2005). Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol 174: 2004-2011. (Pubitemid 40223942)
44. Oldenborg PA, Gresham HD, Lindberg FP. (2001). CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 193: 855-862.
45. Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. (2000). Role of CD47 as a marker of self on red blood cells. Science 288: 2051-2054. (Pubitemid 30397687)
46. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593-598.
47. Reya T, Morrison SJ, Clarke MF, Weissman IL. (2001). Stem cells, cancer, and cancer stem cells. Nature 414: 105-111. (Pubitemid 33041634)
48. Roberts AW, He S, Bradstock KF, Hertzberg MS, Durrant STS, Ritchie D et al. (2008). A phase 1 and correlative biological study of CSL360 (anti-CD123 mAb) in AML. Blood 112: 2956a.
49. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S et al. (2010). Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2: 17ra19.
50. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S et al. (2005). Human lymphoid and myeloid cell development in NOD/ LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174: 6477-6489. (Pubitemid 40663843)
51. Shultz LD, Ishikawa F, Greiner DL. (2007). Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130. (Pubitemid 46174859)
52. Stasi R, Evangelista ML, Buccisano F, Venditti A, Amadori S. (2008). Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev 34: 49-60. (Pubitemid 351168609)
53. Subramanian S, Parthasarathy R, Sen S, Boder ET, Discher DE. (2006). Species- and cell type-specific interactions between CD47 and human SIRPalpha. Blood 107: 2548-2556. (Pubitemid 43348703)
54. Takenaka K, Prasolava TK, Wang JC, Mortin-Toth SM, Khalouei S, Gan OI et al. (2007). Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells. Nat Immunol 8: 1313-1323. (Pubitemid 350138972)
55. Tan BT, Park CY, Ailles LE, Weissman IL. (2006). The cancer stem cell hypothesis: a work in progress. Lab Invest 86: 1203-1207. (Pubitemid 44789910)
56. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. (2008). Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
57. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. (2005). Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092. (Pubitemid 41775913)
58. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T et al. (2010). Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction. Blood 115: 1976-1984.
59. Terwijn M, Feller N, van Rhenen A, Kelder A, Westra G, Zweegman S et al. (2009). Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur J Cancer 45: 1692-1699.
60. Testa U, Riccioni R, Diverio D, Rossini A, Lo Coco F, Peschle C. (2004). Interleukin-3 receptor in acute leukemia. Leukemia 18: 219-226. (Pubitemid 38240035)
61. Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S et al. (2005). High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 11: 6520-6527. (Pubitemid 41338990)
62. Van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B et al. (2007). The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666. (Pubitemid 47523190)
63. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951.
64. Wang PL, O'Farrell S, Clayberger C, Krensky AM. (1992). Identification and molecular cloning of tactile. A novel human T cell activation antigen that is a member of the Ig gene superfamily. J Immunol 148: 2600-2608.
65. Yalcintepe L, Frankel AE, Hogge DE. (2006). Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108: 3530-3537.
66. Zhao X, Singh S, Pardoux C, Zhao J, Hsi ED, Abo A et al. (2010). Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95: 71-78.